We have a robust framework in place to comprehensively manage all significant risks to which we may be exposed and we act in accordance with the guidance set out in Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories and supplementing Commission Delegated Regulation (EU) No 153/2013.
